Two recent events have served to highlight the range of difficult questions raised by pharmaceuticals regulation. Last week, a man died in the French city of Rennes after a clinical trial of a painkiller went tragically wrong. In New York last month, the company controlled by former hedge fund manager Martin Shkreli, raised the price of the life-saving drug, Daraprim, from $13.50 a tablet to $750.
Tag Search Results
20 January 2016, Financial Times
21 October 2015, Financial Times
Bad events in organisations are generally the product of bad systems rather than bad people. So, while it is right to place responsibility for the VW scandal with the chief executive rather than the individuals who falsified emissions tests, we need to go on and ask what it is about modern corporate life that has made such misbehaviour not only possible but appear increasingly common.
17 October 2015, Prospect
If the capital costs of Heathrow expansion could be substantially reduced and its actual financing costs were also trimmed, that project would merit further consideration. Otherwise, a second runway at Gatwick appears simpler, cheaper, less risky and less politically unpalatable.
25 March 2015, Financial Times
A mechanism of funding pharmaceutical research which leads to drug prices far in excess of marginal cost is bound to lead to anguish and injustice. But is there a better idea?
04 March 2015, Financial Times
Michael Porter warned on the danger of being “stuck in the middle”. Companies, he said, must either gain a cost advantage or emphasise product differentiation. But what really matters is enjoying a competitive advantage in the market position you choose.
13 August 2014, Financial Times
Established companies in all industries are inhibited in their response to radical change by vested interests inherent in their existing business models. Now, in publishing, it’s time for the author to be placed where he or she should be – in charge.
25 June 2014
Can Britain’s NHS really be the best in the world – except for keeping its patients alive? John reviews the paradox.
07 May 2014
The history of ICI and the British pharmaceutical industry may provide some pointers to show how shareholders and policymakers should react to Pfizer’s bid for Astra Zeneca.
23 April 2014, Financial Times
Taxi licensing illustrates regulatory capture, the phenomenon by which regulation intended to serve the public is hijacked by industry interests.
26 March 2014, Financial Times
Just as dammed water finds new channels of escape, crowdfunding seems to provide a way around the blockage.
14 January 2011, Scottish Affairs
You can search for all articles relating to a 'tag' by clicking on the relevant 'tag' word above. The size of the word indicates how many articles are available with the 'tag'.